However, there was no significant variation of serum sCD14 among the different groups classified according to age (≤35; 36-55; >55), the stage of tumor (I; IIa; IIb; IIIa), the size of tumor (≤2cm; 2-5cm; >5cm), the intensity of Her2-positive (Her2+; Her2++; Her2+++), or the lymph node (1-3; 4-9; ≥10) (Figure S1). This evidence concerns the gene ERBB2 and neoplasm.